Both strategies demonstrated enhanced cytotoxicity in preclinical models (64, 65), and early clinical data suggest that targeting T cell exhaustion (e.g., GT316) or cytokine signaling (e.g., GT201) may overcome barriers such as IL-2 deficiency or T cell dysfunction in the cervical cancer TME (64, 66, 67). This evidence concerns the gene IL2 and cervical cancer.